View Item 

Show simple item record

Lack of an Effect of Oral Iron Administration on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients
dc.contributor.authorGelone, Daniele K.en_US
dc.contributor.authorPark, Jeong M.en_US
dc.contributor.authorLake, Kathleen D.en_US
dc.date.accessioned2012-03-16T15:53:23Z
dc.date.available2012-03-16T15:53:23Z
dc.date.issued2007-09en_US
dc.identifier.citationGelone, Daniele K.; Park, Jeong M.; Lake, Kathleen D. (2007). "Lack of an Effect of Oral Iron Administration on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27(9). <http://hdl.handle.net/2027.42/90055>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90055
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherMycophenolate Mofetilen_US
dc.subject.otherPolysaccharide Iron Complexen_US
dc.subject.otherDrug Interactionsen_US
dc.subject.otherRenal Transplantationen_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherFerrous Sulfateen_US
dc.titleLack of an Effect of Oral Iron Administration on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine–Nephrology, University of Michigan Medical School, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Clinical Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Pharmacy Practice and Administration, University of the Sciences in Philadelphia, Philadelphia, Pennsylvaniaen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90055/1/phco.27.9.1272.pdf
dc.identifier.doi10.1592/phco.27.9.1272en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceRoche Laboratories Inc. CellCept (mycophenolate mofetil) package insert. Nutley, NJ; 2005.en_US
dc.identifier.citedreferenceEuropean Mycophenolate Mofetil Cooperative Study Group. Placebo‐controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345 ( 8961 ): 1321 – 5.en_US
dc.identifier.citedreferenceHalloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double‐blind, clinical studies in prevention of rejection. The international mycophenolate mofetil renal transplant study groups. Transplantation 1997; 63 ( 1 ): 39 – 47.en_US
dc.identifier.citedreferenceSollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. renal transplant mycophenolate mofetil study group. Transplantation 1995; 60 ( 3 ): 225 – 32.en_US
dc.identifier.citedreferenceKobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005; 80 ( 2 suppl ): S235 – 43.en_US
dc.identifier.citedreferenceHebert MF, Ascher NL, Lake JR, et al. Four‐year follow‐up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67 ( 5 ): 707 – 12.en_US
dc.identifier.citedreferencePawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post‐transplant. J Clin Pharm Ther 2006; 31 ( 1 ): 27 – 34.en_US
dc.identifier.citedreferencePillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 2001; 34 ( 1 ): 77 – 81.en_US
dc.identifier.citedreferenceTakahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS‐61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS‐61443 investigation committee—Japan. Transplant Proc 1995; 27 ( 1 ): 1421 – 4.en_US
dc.identifier.citedreferencevan Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double‐blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68 ( 2 ): 261 – 6.en_US
dc.identifier.citedreferenceWeber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic‐pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13 ( 3 ): 759 – 68.en_US
dc.identifier.citedreferenceArmstrong VW, Shipkova M, Schutz E, Weber L, Tonshoff B, Oellerich M. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc 2001; 33 ( 1–2 ): 1040 – 3.en_US
dc.identifier.citedreferenceOellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Ther Drug Monit 2000; 22 ( 1 ): 20 – 6.en_US
dc.identifier.citedreferenceNicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998; 31 ( 5 ): 329 – 33.en_US
dc.identifier.citedreferenceBullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single‐dose oral and intravenous administration. J Clin Pharmacol 1996; 36 ( 4 ): 315 – 24.en_US
dc.identifier.citedreferenceBullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34 ( 6 ): 429 – 55.en_US
dc.identifier.citedreferenceMeiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18 ( 2 ): 143 – 9.en_US
dc.identifier.citedreferencevan Gelder T, Meur YL, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28 ( 2 ): 145 – 54.en_US
dc.identifier.citedreferenceBullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996; 41 ( 6 ): 513 – 16.en_US
dc.identifier.citedreferenceMorii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000; 68 ( 6 ): 613 – 16.en_US
dc.identifier.citedreferenceCampbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 1991; 31 ( 3 ): 251 – 5.en_US
dc.identifier.citedreferenceLidgate D, Brandl M, Holper M, Abubakari A, Wu X. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm 2002; 28 ( 10 ): 1275 – 83.en_US
dc.identifier.citedreferenceLorenz M, Wolzt M, Weigel G, et al. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am J Kidney Dis 2004; 43 ( 6 ): 1098 – 103.en_US
dc.identifier.citedreferenceMudge DW, Atcheson B, Taylor PJ, et al. The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation 2004; 77 ( 2 ): 206 – 9.en_US
dc.identifier.citedreferenceDucray PS, Gerber M, Boutouyrie B, Zandt H. Absence of an interaction between iron and mycophenolate mofetil absorption. Br J Clin Pharmacol 2006; 62 ( 4 ): 492 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.27.9.1272.pdf
Size:
67.90KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.